SLAM-family receptors: immune regulators with or without SAP-family adaptors.
about
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatmentSpotlight on elotuzumab in the treatment of multiple myeloma: the evidence to dateA polymorphism in a phosphotyrosine signalling motif of CD229 (Ly9, SLAMF3) alters SH2 domain binding and T-cell activationCD84 negatively regulates IgE high-affinity receptor signaling in human mast cellsMigration of myeloid cells during inflammation is differentially regulated by the cell surface receptors Slamf1 and Slamf8The adaptor protein SAP directly associates with CD3ζ chain and regulates T cell receptor signaling.SAP-mediated inhibition of diacylglycerol kinase α regulates TCR-induced diacylglycerol signaling.Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategyImproved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2.CRACC-CRACC interaction between Kupffer and NK cells contributes to poly I:C/D-GalN induced hepatitis.Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression.Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 Receptors.Wild-Type Measles Virus is Intrinsically Dual-Tropic.Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.Activation by SLAM Family Receptors Contributes to NK Cell Mediated "Missing-Self" Recognition.Roles of CD48 in regulating immunity and tolerance.The human 2B4 and NTB-A receptors bind the influenza viral hemagglutinin and co-stimulate NK cell cytotoxicity.Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma.Deletion of Slam locus in mice reveals inhibitory role of SLAM family in NK cell responses regulated by cytokines and LFA-1.Controlling natural killer cell responses: integration of signals for activation and inhibition.EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization.SAP-Dependent and -Independent Regulation of Innate T Cell Development Involving SLAMF Receptors.Control of early stages in invariant natural killer T-cell development.Cytoskeletal dynamics: concepts in measles virus replication and immunomodulation.Signaling in lymphocyte activation.Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.A hematopoietic cell-driven mechanism involving SLAMF6 receptor, SAP adaptors and SHP-1 phosphatase regulates NK cell education.Efficacy and safety of elotuzumab for the treatment of multiple myeloma.SLAM-associated protein favors the development of iNKT2 over iNKT17 cells.Siglec-7 Defines a Highly Functional Natural Killer Cell Subset and Inhibits Cell-Mediated Activities.ICOS, SLAM and PD-1 expression and regulation on T lymphocytes reflect the immune dysregulation in patients with HIV-related illness with pulmonary tuberculosis.Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.Endothelial cells express NKG2D ligands and desensitize anti-tumor NK responses.Unbiased Quantitative Proteomics Reveals a Crucial Role of the Allergen Context for the Activation of Human Dendritic Cells.Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor.A compound chimeric antigen receptor strategy for targeting multiple myeloma.Decreased microRNA-142-3p/5p expression causes CD4+ T cell activation and B cell hyperstimulation in systemic lupus erythematosus.Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells
P2860
Q26738944-0CE93516-1181-4563-B9FE-198E30BA72E8Q28076147-96DA6D4B-8754-4D9F-AB61-087A154C262BQ28115070-75B149F7-5922-4A42-AD41-A1D9A399A9CBQ28118474-521522EE-E493-4534-AC43-83486953005BQ28504904-74A4FC7F-E727-43CF-B71B-E97F9F96FE38Q30010025-C58FB5AE-035E-4A3F-A3A7-9026D8E62079Q30010214-70A2929B-64D8-4392-AA6F-0F4671F4C05AQ30249513-B49A9B07-7C6A-4B52-A067-F72D5CD5448DQ33749309-D4EA0D7C-FBC2-494B-BB51-51E12555FCDFQ34080911-56D3A3D2-3A14-4372-A1E2-CE45DE31770AQ35010377-94E2DC10-8034-4C7E-A4A2-67EB8C2F88AFQ35077803-E342A879-D6FA-43B5-B3CD-FF9F9AF42FBEQ35408407-97458085-F412-4CC7-BB8F-38E944E93548Q35747417-E15ABFEE-2E73-48A1-BE6F-23669C4E5789Q35909663-6B4B154B-630F-4F5B-A48C-AA4F6B0B2FC3Q35982359-785825D1-9613-4893-8079-05812B4A3473Q36883146-8DDF11AC-E6FC-44EC-BD3F-A074EAB1CA0AQ37022389-5C1C901A-326B-4562-92BF-08E87D71D47CQ37138519-BD3B0728-46A6-4072-BD4B-C9D1CB47BE18Q37272136-A1FFE8EB-FF0C-428A-ADF6-04D87C5A56AAQ37404156-EF2C7BFC-6881-4BAB-B3E5-ED84F1400FD6Q37689394-7D126797-75EA-4279-B598-AA94FCA5D83FQ37734849-7DE61AA9-384C-4BEA-842C-0169AC5DF690Q37896127-4675996C-6D84-4684-9A17-00BE4BF523EAQ37952177-055E17C0-2C75-4E35-A1B1-8035CC284B79Q38511575-95343BD7-15EA-4EB2-8489-FF31066E6938Q38526452-73FA295A-23AF-42DF-B4EB-8DA636420FB5Q38794091-55EBFAC0-2865-4591-8C49-FE2CB86EE388Q39070515-0576F2BD-FB21-4FAC-ACBD-8CBF86AAEA99Q39659304-50CFA5C9-7B35-452E-A4AB-D2412029A916Q39677106-A902D521-462F-43E7-B90D-1FE88D56254BQ41109220-491A4413-9253-4EC7-9604-D546A4B46851Q43107156-EADE7ED7-467C-45B2-8F68-28079BEA3CADQ46018291-59D3779A-C53D-48A3-A79F-B0440B8C1EFBQ47124635-6C98C2CF-C4C6-4649-AC51-525B8FB00317Q47250902-EE9A5C99-6A07-47BC-A379-39D31D8A2F42Q48649390-93AF2F28-ACA6-4B66-AF28-CAE4F7F0C043Q54312096-6E7027BD-0D35-4E6D-8A4D-CC06AC71CB52Q55310350-9C698C52-B9D0-4CF5-B3C7-350ACDF95C98Q57039192-66713497-61CB-422F-81BF-0A2F3E483983
P2860
SLAM-family receptors: immune regulators with or without SAP-family adaptors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
SLAM-family receptors: immune regulators with or without SAP-family adaptors.
@ast
SLAM-family receptors: immune regulators with or without SAP-family adaptors.
@en
type
label
SLAM-family receptors: immune regulators with or without SAP-family adaptors.
@ast
SLAM-family receptors: immune regulators with or without SAP-family adaptors.
@en
prefLabel
SLAM-family receptors: immune regulators with or without SAP-family adaptors.
@ast
SLAM-family receptors: immune regulators with or without SAP-family adaptors.
@en
P2860
P1476
SLAM-family receptors: immune regulators with or without SAP-family adaptors.
@en
P2093
André Veillette
P2860
P304
P356
10.1101/CSHPERSPECT.A002469
P577
2010-03-01T00:00:00Z